Patient characteristics | |
 Sex | |
  Men | 81 |
  Women | 53 |
 Age [y] | |
  Median | 67.5 |
  Min | 21 |
  Max | 87 |
 Weight [kg] | |
  Median | 80 |
  Min | 45 |
  Max | 140 |
 Height [m] | |
  Median | 1.71 |
  Min | 1.51 |
  Max | 1.93 |
 BMI [kg/m2] | |
  Median | 27.34 |
  Min | 17.58 |
  Max | 43.82 |
Therapy regimen | |
 Clinical trials | |
  CAO/ARO/AIO-04 | 111 |
  TransValid-KFO179/GRCSG-A | 15 |
  TransValid-KFO179/GRCSG-B | 8 |
 Therapy sequence | |
  RCT-TME-CT | 126 |
  RCT-CT-TME | 8 |
CT characteristics | |
 CT regimen | |
  5-FU-mono | 78 |
  FOLFOX | 56 |
 5-FU plasma levels (AUC [mg∙h/l]) | |
  Median | 20.37 |
  Min | 2.02 |
  Max | 100.00 |
RT characteristics | |
 RT technique |  |
  3DCRT | 87 |
  IMRT | 2 |
  VMAT | 31 |
  3DCRT and VMAT | 14 |
PTV size [cm3] | |
  Median | 1414.7 |
  Min | 998.6 |
  Max | 2735.5 |